Glucotrace

Glucotrace is a radiopharmaceutical containing the active ingredient fludeoxyglucose (18F) supplied as a sterile solution for injection. It is administered intravenously under prescription in the European Union and is used primarily for diagnostic imaging with positron emission tomography (PET). The compound exploits glucose metabolism to highlight areas of increased cellular activity in various clinical examinations.

Glucotrace is indicated for PET imaging to assess metabolic activity in several organ systems. It assists clinicians in diagnosing and staging disease based on glucose uptake patterns.

- Oncologic PET imaging for detection and staging of malignant tumors. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurological PET imaging for assessment of epilepsy, dementia, and brain metabolism. - Research applications investigating glucose metabolism in clinical trials. - Whole‑body PET scans for comprehensive disease evaluation.

Adverse reactions to Glucotrace are generally mild and related to the injection procedure or the radiopharmaceutical itself. Serious events are rare but may occur.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or vomiting shortly after administration. - Temporary headache or dizziness. - Low‑grade allergic skin reactions such as erythema. - Mild increase in serum glucose levels in susceptible patients.

Serious: - Severe hypersensitivity reactions including anaphylaxis. - Significant radiation‑induced tissue injury (extremely rare). - Acute renal impairment in patients with pre‑existing kidney disease. - Cardiovascular events such as arrhythmia in high‑risk individuals. - Persistent neurologic symptoms following brain PET in rare cases.

Glucotrace should be used with careful consideration of patient-specific factors and procedural guidelines to minimize risks.

- Verify patient fasting status and blood glucose levels before administration. - Assess renal function, especially in patients with chronic kidney disease. - Use the lowest effective activity dose consistent with diagnostic quality. - Monitor for immediate allergic reactions during and after injection. - Pregnant or breastfeeding women should only receive Glucotrace when clearly justified. - Ensure proper radiation safety measures for staff and surrounding individuals. - Document any prior reactions to radiopharmaceuticals in the patient’s record.

Glucotrace may interact with other substances that affect glucose metabolism or radiation exposure. Consider these interactions when planning imaging studies.

Avoid: - Concurrent administration of high‑dose glucose‑lowering agents that could mask tracer uptake. - Use of other radiopharmaceuticals within 24 hours that may cause cumulative radiation dose. - Administration of iodinated contrast agents immediately before PET, which can alter biodistribution.

Use with caution: - Medications that significantly raise blood glucose (e.g., corticosteroids, certain antipsychotics). - Diabetic treatments that cause rapid glucose fluctuations. - Drugs affecting renal clearance, potentially altering tracer elimination. - Patients receiving chemotherapy or targeted therapies that modify tumor metabolism. - Any investigational agents that may compete for glucose transport mechanisms.